Aspeya
David Duff is an accomplished procurement professional with extensive experience in the pharmaceutical industry. Currently serving as VP Procurement at Vectura Fertin Pharma since January 2023 and as Vice President of Procurement for Global Innovation & Development at Phillips Medisize since January 2025, David has held several key positions at Vectura Group and GlaxoSmithKline. Notably, David was Senior Procurement Director for Europe at GlaxoSmithKline, overseeing an indirect spend of approximately £800 million, where responsibilities included financial delivery, risk management, and supply chain resolution. David's procurement expertise spans across multiple roles, including leading strategic initiatives in new product supply, managing significant site spend, and supporting technology transfers internationally. David holds a Bachelor's Degree in Applied Microbiology from the University of Strathclyde and is a member of the Chartered Institute of Purchasing & Supply, with additional accreditation in Operational Excellence.
This person is not in any teams
This person is not in any offices
Aspeya
We are on a journey to empower healthier lifestyles and target specific unmet needs. We do this by being innovative, optimizing formulas, and applying rigorous scientific standards. This involves harnessing deep insight and scientific substantiation to reimagine how ingredients can be used, and working towards the development and commercialization of a pipeline of wellness and healthcare products and brands. We are applying our expertise to innovate in four areas of focus: Consumer health, cannabinoids, inhaled therapeutics, and nicotine replacement therapy. Our people are open-minded thinkers, leading-edge scientists, and knowledgeable innovators. Want to join our team? Visit our careers site to search for opportunities: careers.aspeya.com